Chugai Pharmaceutical is developing a new synthetic research facility at its existing location in Kita-ku, Tokyo, Japan.
Announced in June 2018, construction on the new research facility is expected to begin in October 2018 and is scheduled for completion by November 2019. Operations are estimated to commence by January 2020.
Chugai Pharmaceutical is investing CNY4.5bn ($40.5m) in the project, which is expected to enhance the process development for small and middle molecule active pharmaceutical ingredients (API).
Chugai Pharmaceutical’s existing Ukima Research Laboratories in Kita-ku is built on a 31,323m² site and has a total floor area of 59,198m².
The research activities carried out at Ukima Research Laboratories include API manufacturing and product design. The facility also develops quality testing methods and analyses the structure and physical properties of pharmaceuticals.
Chugai Pharmaceutical’s new synthetic research facility will be a six-storey building with a total site area of 985m² and floor area of 4,925m².
Advanced containment technologies and research equipment will be installed, which will be leak-proof to protect researchers from being exposed to harmful chemical compounds.
The layout of the new facility will be designed to improve communication among researchers. The facility will be equipped with high-potency API (HPAPI) facilities, which will enable Chugai Pharmaceutical to carry out process development ranging from early development to commercial production of new drug candidates.
The new facility will enable an expansion of existing research activities in regards to high-potency APIs. It will carry out synthetic research, which is expected to further strengthen the process development for small and middle molecule APIs.
The project is aimed to accelerate innovation and productivity through research by speeding up the development processes for new middle molecule pharmaceuticals.
Small molecule drugs penetrate into cells but cannot block protein-protein interactions. They have a molecular weight of 500g per mole (gm/mol), are manufactured through organic synthesis and can be administered either orally or through injection method. Conversely, therapeutic antibodies can act on specific target bodies but cannot pass through cell membranes due to their size.
Middle molecule drugs combine the advantages of both small molecule drugs and therapeutic antibodies. They are able to reach targets that are unapproachable by small molecule drugs and therapeutic antibodies alone, as they have the capability to enter cells and act actively and specifically on targets.
These next-generation medicines have a molecular weight in the range of 500gm/mol and 2,000gm/mol.
Based in Tokyo, Chugai Pharmaceutical is a research-based pharmaceutical company that manufactures biotechnological products.
The company specialises in prescription pharmaceuticals and is a member of the Roche Group. It develops innovative products to satisfy unmet medical needs with a specific focus in the field of oncology.
Chugai Pharmaceutical’s research facilities are located in Gotemba and Kamakura in Japan. The company also operates a facility in Singapore, which focuses on generating novel antibody drugs using its proprietary innovative antibody engineering technologies.
Chugai Pharma USA and Chugai Pharma Marketing are two subsidiaries of Chugai Pharmaceutical, which are involved in clinical development activities in the US and Europe.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…